| 10.31 -0.17 (-1.62%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.87 |
1-year : | 17.23 |
| Resists | First : | 12.73 |
Second : | 14.76 |
| Pivot price | 11.5 |
|||
| Supports | First : | 9.47 | Second : | 7.87 |
| MAs | MA(5) : | 10.24 |
MA(20) : | 11.74 |
| MA(100) : | 13 |
MA(250) : | 11.3  |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 20.2 |
D(3) : | 13.4 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 17.25 | Low : | 5.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DSGN ] has closed above bottom band by 19.5%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.52 - 10.58 | 10.58 - 10.63 |
| Low: | 9.98 - 10.06 | 10.06 - 10.13 |
| Close: | 10.19 - 10.31 | 10.31 - 10.41 |
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Sun, 04 Oct 2026
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
Fri, 02 Oct 2026
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program - Seeking Alpha
Mon, 27 Jul 2026
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Mon, 18 May 2026
Design Therapeutics stock surges on positive trial data - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 31.8 (%) |
| Held by Institutions | 78.7 (%) |
| Shares Short | 6,620 (K) |
| Shares Short P.Month | 5,540 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.6 % |
| Return on Equity (ttm) | -34.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.94 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -8.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|